Volume 50, Issue 3, Pages (September 2006)

Slides:

Advertisements

Similar presentations

Volume 41, Issue 3, Pages (March 2002)

Advertisements

Assessment and management of male lower urinary tract symptoms (LUTS)

Volume 59, Issue 2, Pages (February 2011)

Volume 68, Issue 3, Pages (September 2015)

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Volume 67, Issue 1, Pages (January 2015)

Volume 54, Issue 6, Pages (December 2008)

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Assessment and management of male lower urinary tract symptoms (LUTS)

Volume 64, Issue 2, Pages (August 2013)

Volume 67, Issue 6, Pages (June 2015)

Volume 50, Issue 6, Pages (December 2006)

Volume 52, Issue 2, Pages (August 2007)

Rowland Illing European Urology Supplements

Volume 45, Issue 4, Pages (April 2004)

Volume 56, Issue 1, Pages (July 2009)

Volume 59, Issue 2, Pages (February 2011)

Volume 55, Issue 2, Pages (February 2009)

The Long-Term Outcome of Medical Therapy for BPH

Volume 63, Issue 1, Pages (January 2013)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Back to the Future: Introduction and Conclusions

Volume 51, Issue 1, Pages (January 2007)

Volume 52, Issue 3, Pages (September 2007)

Volume 56, Issue 3, Pages (September 2009)

Volume 62, Issue 3, Pages (September 2012)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Rowland Illing European Urology Supplements

Volume 64, Issue 4, Pages (October 2013)

Volume 60, Issue 1, Pages (July 2011)

Volume 55, Issue 3, Pages (March 2009)

Volume 56, Issue 1, Pages (July 2009)

Volume 58, Issue 3, Pages (September 2010)

Volume 60, Issue 4, Pages (October 2011)

Volume 61, Issue 3, Pages (March 2012)

Volume 69, Issue 2, Pages (February 2016)

Volume 71, Issue 4, Pages (April 2017)

Volume 58, Issue 5, Pages (November 2010)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old P. Perrin,

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.

The Economic Costs of Overactive Bladder in Germany

Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl European Urology

Volume 54, Issue 4, Pages (October 2008)

Volume 50, Issue 3, Pages (September 2006)

Volume 50, Issue 5, Pages (November 2006)

Volume 46, Issue 5, Pages (November 2004)

Volume 51, Issue 1, Pages (January 2007)

Volume 52, Issue 5, Pages (November 2007)

Volume 74, Issue 5, Pages (November 2018)

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Volume 54, Issue 6, Pages (December 2008)

Volume 75, Issue 2, Pages (February 2019)

Volume 74, Issue 3, Pages (September 2018)

Volume 53, Issue 6, Pages (June 2008)

Volume 74, Issue 4, Pages (October 2018)

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results from the EPIC.

Martin Michel, Jean de la Rosette European Urology Supplements

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Profile of Silodosin European Urology Supplements

Classification of Mixed Incontinence

Economic and Social Impact of OAB

Volume 52, Issue 6, Pages (December 2007)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Presentation transcript:

Volume 50, Issue 3, Pages 440-453 (September 2006) The Placebo Effect in the Pharmacologic Treatment of Patients with Lower Urinary Tract Symptoms Jules H. Schagen van Leeuwen, Ramiro Castro, Michael Busse, Bart L.H. Bemelmans European Urology Volume 50, Issue 3, Pages 440-453 (September 2006) DOI: 10.1016/j.eururo.2006.05.014 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Efficacy of the stress urinary incontinence (SUI) and overactive bladder (OAB)/urge urinary incontinence drugs versus placebo in SUI as measured by the percentage reduction of incontinence episodes (IEs). Dulox=duloxetine; Sol=solifenacin; Tol=tolterodine; Trosp=trospium; Oxy=oxybutynin; Dar=darifenacin. For data retrieval see Table 1. European Urology 2006 50, 440-453DOI: (10.1016/j.eururo.2006.05.014) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Efficacy of drugs versus placebo in overactive bladder (OAB) and bladder outlet obstruction/benign prostatic enlargement (BOO/BPE) as measured by the percentage change in voided volume (VV) per micturition or peak flow rate (Qmax), respectively, compared to baseline. No data were available for oxybutynin. Sol=solifenacin; Tol=tolterodine; Tros=trospium; Dar=darifenacin; Alf=alfuzosin; Tam=tamsulosin; Dox=doxazosin; Ter=terazosin; Fin=finasteride; Dut=dutasteride. Data from more than one randomised controlled trial (RCT) assessing a particular drug have been averaged over all RCTs reported. For data retrieval see Table 1. European Urology 2006 50, 440-453DOI: (10.1016/j.eururo.2006.05.014) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 3 Efficacy of drugs versus placebo in bladder outlet obstruction/benign prostatic enlargement (BOO/BPE) as measured by the percentage reduction of BOO/BPE symptom score (International Prostate Symptom Score, adapted American Urological Association score or Boyarsky) compared to baseline. Alf=alfuzosin; Tam=tamsulosin; Dox=doxazosin; Ter=terazosin; Fin=finasteride: Dut=dutasteride. Data from more than one randomised controlled trial (RCT) assessing a particular drug have been averaged over all RCTs reported. For data retrieval see Table 1. European Urology 2006 50, 440-453DOI: (10.1016/j.eururo.2006.05.014) Copyright © 2006 European Association of Urology Terms and Conditions